Our skin is one of our hardest working organs. It not only protects all the other organs in our bodies, and can repair itself, but it also regulates body temperature and detects and fights off infection. Healthy skin is an essential part of your overall health and wellness, yet most of us take our skin for granted, especially in the winter.

Winters Effects on Skin

Frequent hand washing and sanitizer use may already be taking a toll on your hands as the pandemic continues, but as temperatures and humidity levels continue to drop, other body parts can also get itchy, cracked, and irritated.

The harsh weather can strip the skins natural protective barrier, creating gaps in the outer most layer, allowing water to escape promoting dehydration and irritants to get in. The dry environment may be responsible for that uncontrollable itch, as the inflammatory response kicks in and releases histamines. It can exacerbate inflammatory skin diseases such as rosacea, eczema, ichthyosis, and psoriasis, which suffer an impaired barrier function.

Tips to Avoid a Painful Season

If you are not prepared, the changes to your skin can make for a long winter. Knowing how your skin typically reacts to cold weather can help you create a routine ahead of time and keep your skin from reacting negatively to fall and winter.

Know Your Skin: As winter approaches, try to remember how your skin changed during past winters. Maybe your skin stayed the same as it did in the summer. This could be because of the routine you have in place. If your skin changed and became dryer than usual, this may mean you need to better prepare your skin for winter.

If you know your skin is prone to drying out from cold weather, a way to prepare your skin before and during the winter is to stick to short and warm showers. Long, hot showers can feel great after a cold day, but can strip your skin of important oils, leaving it dry.

Its All About Moisture: Find a good moisturizer and use it before the cold weather hits and throughout the cold weather season. A moisturizer does exactly what its name implies: moisturizes. Moisturizing your skin in preparation for the cold weather and during the winter can help your skin from becoming dried out. An oil-free moisturizer that contains glycerin is best to help keep skin hydrated.

Some Conditions Require Special Treatment: If you have eczema or psoriasis, you will have to do more than simply slather on extra lotion and drink more water.

Preparation Can Go a Long Way

Dry skin can make for an uncomfortable winter which is why preparation is key as we continue through the cold winter months. If youre having trouble managing your skin care, talk to a dermatologist. Your dermatologist can help you develop a routine and care plan to meet your skins unique needs. If youre experiencing severely dry or chapped skin, or if youve recently developed a rash thats not improving, talk to your doctor as these could be signs of a dermatologic condition or symptoms of more serious illness or allergic reaction.

Dr. Sabrina Mikita is a dermatologist with UPMC seeing patients at SH Dermatology located at 1205 Grampian Blvd., Suite 1A, Williamsport. For more information or to schedule an appointment, call (570) 326-8060

Excerpt from:

UPMC doctor: tips to prevent cold weather skin issues - NorthcentralPa.com

Visit the News Hub

New grant to fund research into drugs that showed promise in small study of people with Crohns disease

Meals prepared for scientific studies of metabolism and nutrition stand ready for distribution at Washington University School of Medicine in St. Louis. Researchers at the School of Medicine are studying whether drugs to treat inflammatory conditions such as Crohn's disease also could help control blood sugar levels.

Inflammation and metabolic disorders are deeply intertwined. For example, people with inflammatory conditions such as Crohns disease and psoriasis are at risk of developing metabolic disorders such as insulin resistance and diabetes. However troubling that connection might seem, it also might point to some promising news.

Researchers at Washington University School of Medicine in St. Louis have received a Catalyst grant from the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) to investigate whether immunosuppressive drugs prescribed for inflammatory bowel disease (which includes Crohns disease and ulcerative colitis) or psoriasis also can control blood sugar levels. If they do, such drugs could provide a way to improve control of blood sugar in people with inflammatory diseases, thereby reducing the risk of serious complications such as diabetes. Catalyst grants are meant to support scientists of exceptional creativity who propose pioneering and possibly transformative approaches important to the mission of the NIDDK.

The idea for the study emerged from an unexpected observation. Gwendalyn Randolph, PhD, the Emil R. Unanue Distinguished Professor of Immunology and a professor of medicine, was investigating how people with Crohns disease handle fat in their diet by feeding participants a carefully designed milkshake and monitoring the levels of different kinds of fat in their blood over time. As part of the study, the researchers also collected data on blood sugar levels. The primary result of that study was negative: People with Crohns and healthy participants processed fat much the same. But an odd pattern in the data caught Randolphs eye: The five Crohns patients who happened to be taking the anti-inflammatory drug ustekinumab maintained normal blood sugar levels after a meal, unlike other participants with Crohns disease who were taking other medications. Their glucose levels strayed higher and normalized more slowly than healthy controls.

It was really just a side observation; the study was not designed to address the question of blood glucose levels, said Randolph, the principal investigator on the $500,000 NIH grant. But this new grant will help us check it out and see if it has merit. Its an exciting hypothesis because people with inflammatory bowel disease (IBD) are at higher risk of developing metabolic disorders including type 2 diabetes, and there are not great medications to treat glucose problems linked to inflammatory disease.

As a drug that might control blood sugar, ustekinumab may be a dark horse. Scientists have speculated for years that suppressing pro-inflammatory molecules known as cytokines might help control blood sugar in people with chronic inflammation. But there are dozens of cytokines, and none of them have panned out in clinical trials. The two cytokines suppressed by ustekinumab IL-12 and IL-23 have never been high enough on the list of likely targets to warrant a study.

The serendipitous observation suggests that IL-12 and IL-23 may have previously unrecognized effects that could shine light on the complicated relationship between metabolism and inflammation.

We caught a glimpse of something, in the previous study, related to how metabolism is modified in the setting of inflammation, said co-investigator Parakkal Deepak, MBBS, an assistant professor of medicine in the Division of Gastroenterology. As a member of the medical faculty of the Inflammatory Bowel Disease Center, Deepak sees patients with IBD on the Washington University Medical Campus. With further investigation into this area, we one day may be able to select therapy for people with inflammatory diseases based on the underlying metabolic profile and the effect of specific treatments on that metabolic profile.

The researchers plan to study patients who have inflammatory diseases and already are taking drugs that target IL-12 or IL-23. With the help of the Center for Human Nutrition, the researchers will monitor levels of blood sugar and other biomolecules while participants are fasting and after meals. Bettina Mittendorfer, PhD, a professor of medicine in the Division of Geriatrics and Nutrition Sciences and an expert on glucose metabolism, is helping to design the study in people.

The researchers also are planning mouse studies to see if neutralizing IL-12, IL-23 or both improves glucose and insulin tolerance.

The implications are much larger than diabetes alone, said co-investigator Matthew Ciorba, MD, an associate professor of medicine in the Division of Gastroenterology and director of the IBD Center. There are several other important complications of IBD linked to glucose metabolism, notably nonalcoholic fatty liver disease. Understanding if current therapies can modify glucose and other metabolic complications has the potential to impact millions of patients across the world.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the article here:

Scientists to explore whether anti-inflammatory drugs control blood sugar Washington University School of Medicine in St. Louis - Washington...

Spondyloarthritis is an umbrella term that describes different types of arthritis. These types mainly affect the spine, but they can also cause symptoms in other parts of the body.

There has been some debate about whether spondyloarthritis is an autoimmune condition or an autoinflammatory condition. However, recent research suggests that spondyloarthritis is indeed an autoimmune condition.

This article will explore spondyloarthritis in detail. Specifically, it will examine the different types, symptoms, and treatment options associated with the condition.

There are several subtypes of spondyloarthritis. Each can involve a different part of the body.

The following sections will look at some of these types in more detail.

Ankylosing spondylitis is the most common form of spondyloarthritis. It involves ligaments, tendons, and joint capsules attaching to bones in the spine and peripheral joints.

It can cause the bones in the spine to fuse together, leading to stiffness and immobility.

Learn more about ankylosing spondylitis here.

This type of spondyloarthritis primarily involves the joints in the spine and pelvis.

Axial spondyloarthritis causes back pain and affects around 5.5 million people in the United States.

Like axial spondyloarthritis, the non-radiographic form also affects the spine and causes lower back pain.

However, the effects of non-radiographic spondyloarthritis are not visible on X-rays. They are only visible on more sensitive imaging tests, such as MRI scans.

Peripheral spondyloarthritis describes a number of spondyloarthritis subsets.

It mainly affects the hands and feet. However, it can also cause inflammation in the:

Both rheumatoid arthritis and spondyloarthritis are very common. Although they share some similarities, the conditions also have significant differences.

Spondyloarthritis tends to be more common in males, whereas rheumatoid arthritis is more common in females.

Rheumatoid arthritis symptoms typically start appearing when a person is around 4050 years of age. The symptoms of spondyloarthritis usually occur earlier than this.

The early symptoms of rheumatoid arthritis usually affect the hands and feet. The early symptoms of spondyloarthritis usually start with back pain.

Learn more about the early signs and symptoms of rheumatoid arthritis here.

People often develop spondyloarthritis in their teenage years or 20s. Those with the following characteristics may be more likely to experience spondyloarthritis:

It is important to note that spondyloarthritis is notoriously difficult to diagnose in females. This could mean that it is more common in females than some statistics may show.

Lower back or hip pain is a common early symptom. However, symptoms can vary depending on the type of spondyloarthritis a person has.

Inflammation elsewhere in the body is a symptom of spondyloarthritis. It can especially affect the:

Spondyloarthritis-related inflammation can cause:

Another symptom of spondyloarthritis and the swelling it causes is psoriatic rashes. These may appear differently depending on a persons skin color.

Learn more about psoriasis on black skin here.

These symptoms may be particularly painful first thing in the morning or after periods of rest.

Untreated spondyloarthritis could lead to a person developing the following conditions:

A person who is experiencing symptoms of spondyloarthritis should contact a doctor to treat the condition. This may help prevent these complications.

If a person has had chronic lower back pain since before the age of 40 years, they may have spondyloarthritis. People often assume that they simply have back pain due to poor posture or other mechanical issues.

Because the pain can come and go, some people may assume that the pain is not important. However, not seeking treatment for spondyloarthritis can lead to complications later on.

A person who suspects that they have spondyloarthritis should contact a doctor. They should provide the doctor with details about their pain onset and whether or not they have other inflammatory symptoms that might suggest the presence of spondyloarthritis.

A doctor will diagnose spondyloarthritis by taking a persons medical history and performing a physical exam.

Imaging can help confirm a diagnosis. The doctor may request an MRI scan if an X-ray does not show damage but a person has symptoms that suggest the presence of spondyloarthritis.

A blood test is also available for the HLA-B27 gene, which is a gene associated with the condition. However, testing positive for the gene does not necessarily mean that a person has spondyloarthritis.

The doctor can also perform ESR tests or CRP tests on the blood in order to determine if swelling is present in the body. This can also help diagnose spondyloarthritis.

The doctor may also choose to carry out a complete blood count, to diagnose anemia, or a metabolic panel, to analyze a persons kidney and liver function.

Sometimes, medical professionals can mistake spondyloarthritis for other similar conditions, which can delay diagnosis and treatment. This is especially the case among females.

There is currently no cure for this condition. However, treatment can help relieve the symptoms and slow the progress of the condition.

Some treatment options include:

Biologics are very effective but expensive. These drugs can also increase a persons risk of infection.

Also, physical therapy can help restore range of motion in the affected joints.

One 2020 study involved putting 100 people with axial spondyloarthritis, non-radiographic axial spondyloarthritis, or psoriatic arthritis with axial involvement on physical therapy treatment programs.

The therapy significantly improved the pain that the condition caused, including among those with secondary conditions such as fibromyalgia.

Occupational therapy can also help a person improve or maintain their ability to perform day-to-day activities. An occupational therapist can provide recommendations and assistive devices to help prevent further injury.

Living with spondyloarthritis can make performing certain everyday tasks more difficult, but it is possible to manage the symptoms. Also, the condition does not usually affect a persons life expectancy significantly.

Symptoms such as pain and fatigue may come and go, and treatments can help a person live with this condition.

Some behavioral changes can also make living with spondyloarthritis easier. These changes include:

There are also spondyloarthritis support groups available for people who may need additional support.

Not seeking treatment for spondyloarthritis can lead to complications. Joints can fuse, for example, which may cause severe stiffness or immobility.

The symptoms of spondyloarthritis can come and go. However, even if a person does not constantly experience symptoms, they should still contact a doctor.

Not seeking treatment can lead to more complications of the condition. For example, it could become increasingly painful.

With the right treatment, people with spondyloarthritis can live an active life. Although there is no way to cure the condition, it is possible to manage the symptoms and prevent disease progression.

Making certain behavioral changes and trying medical treatments can make the pain and inflammation of spondyloarthritis more manageable.

Read more:

Spondyloarthritis: Types, symptoms, treatment, and more - Medical News Today

Phototherapy, also known as light therapy, involves exposing the skin to ultraviolet light under medical supervision. Narrow-band UVB (NBUVB), Ultraviolet A (UVA)/NBUVB (in combination), and PUVA (psoralen + UVA) are the common types of phototherapy used. The choice of the type of phototherapy is dependent on the type of skin condition. However, narrow-band UVB is most widely opted due to its versatility and effectiveness for treating psoriasis, eczema, and mycosis fungoides patients across the world.

Furthermore, narrow-band UVB removes redundant and harmful UV rays by emitting wavelengths of 311-312 nm. Phototherapy equipment includes LED phototherapy equipment, fiber-optic phototherapy equipment, and conventional phototherapy equipment.

Request for a sample of this research report @https://www.coherentmarketinsights.com/insight/request-sample/1177

Rising number of psoriasis cases are expected to boost growth of the phototherapy equipment market in the near future. For instance, according to the International Federation of Psoriasis Associations (IFPA), around 150,000 new cases are reported in the U.S every year and 3% of people are affected with some form of psoriasis around the world. Furthermore, increasing number of other skin diseases is increasing the demand for LED-based phototherapy equipment such as high intensity gallium nitric blue light emitting diode, which is very effective in lowering bilirubin by providing much higher irradiance for intensive phototherapy in the treatment of neonatal jaundice. According to the National Center for Biotechnology Information (NCBI), around 13 million babies are afflicted with jaundice globally, each year. This in turn is expected to boost growth of the phototherapy equipment market size. However, high cost of the equipment is hindering growth of the market.

Some of the key players profiled in the study are Atom Medical Corporation, Natus Medical Incorporated, Daavlin, Phoenix Medical Systems Pvt. Ltd, Philips Lighting Holding B.V., Solarc Systems, Inc., and GE Healthcare, Inc.

Get up to 30% Discount on this Premium Report @:https://www.coherentmarketinsights.com/insight/request-discount/1177

Market Taxonomy:

The global phototherapy equipment market is segmented into devices, application, end user, and geography

On the basis of devices, the global phototherapy equipment market is segmented into:

On the basis of application, the global phototherapy equipment market is segmented into:

Apply Promo Code STAYHOME andGet Up to 30%Discount

Buy This Complete A Business Report:https://www.coherentmarketinsights.com/insight/buy-now/1177

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone: US +1-206-701-6702/UK +44-020 8133 4027Email:sales@coherentmarketinsights.com

Follow this link:

Phototherapy Equipment Market 2020 Size, Share, Analysis, Growth Driver and Industry Segments by 2027 KSU | The Sentinel Newspaper - KSU | The...

Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth.

Factors that can trigger psoriasis include infections, heavy alcohol consumption, cold weather, certain medications, smoking, stress and injury to the skin such as bug bite, cut and sever sunburn. The signs and symptoms of psoriasis vary from person to person which includes dry, cracked skin that may bleed, red patches of skin covered with silvery scales, small scaling spots, itching, burning, swollen and stiff joints.

Get Sample Copy of this Report @https://www.persistencemarketresearch.com/samples/3086

Psoriasis may be classified into various types such as plaque psoriasis, scalp psoriasis, pustular psoriasis, psoriatic arthritis, guttate psoriasis, nail psoriasis, erythrodermic psoriasis and inverse psoriasis. Various treatments for psoriasis are oral medication, topical medication and biologics injections.

Psoriasis can also be treating by phototherapy treatment which includes ultraviolet light therapy, laser treatment, tanning beds, psoralen +UVA and sunlight treatment. Psoriasis can occur in any part of the body and it is associated with other health conditions such as heart disease, diabetes and depression.

North America, followed by Europe, has the largest market for systemic psoriasis therapeutics due to emergence of novel therapies and rise in treatment seeking population in the region. Asia is expected to show high growth rate in the systemic psoriasis therapeutics market in next few years due to increase in the awareness of disease in the region.

Get TOC of This Report @https://www.persistencemarketresearch.com/toc/3086

Technological advancement, rise in number of psoriasis patients, development of novel drugs, increasing disease awareness and improvement in diagnostic methods are some of the key factors driving the growth for global systemic psoriasis therapeutics market.

In addition, long-term treatment involving continuous uptake of biologics are expected to drive the market for systemic psoriasis therapeutics. However, adverse side effects associated with psoriatic drugs and economic downturns are some of the key factors restraining the growth for global systemic psoriasis therapeutics market.

Growing demographics and economies in the developing countries such as India and China are expected to offer high growth in systemic psoriasis therapeutics market in Asia. In addition, growing demand of novel therapies for psoriasis treatment is expected to develop good opportunity for global systemic psoriasis therapeutics market.

However, safety concern associated with systemic psoriasis therapeutics is expected to lead a challenge for systemic psoriasis therapeutics market. Some of the major trends that have been observed for systemic psoriasis therapeutics market are increasing use of combination therapies for treating psoriasis, emergence of non-invasive psoriasis treatment and technological advancement in the field.

Get Full Report @https://www.persistencemarketresearch.com/checkout/3086

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Read more from the original source:

Adoption By Emerging Economies To Bolster The Systemic Psoriasis Therapeutics Market Atlantic Financial Management - Atlantic Financial Management

The use of biologic agents among patients with moderate to severe psoriasis infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), was associated with a lower risk for COVID-19-related hospitalization compared with patients who used non-biologic system agents, according to findings from a registry analysis published in the Journal of Allergy and Clinical Immunology.

There were 2 data sources reviewed in this registry-based study: the international Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 infecTion (PsoProtect) and the self-report patient-facing registry PsoProtectMe. The PsoProtect included clinician-reported diagnoses of confirmed or suspected COVID-19 in patients with psoriasis, whereas the patient-facing registry provided data on risk-mitigating behaviors.

There was a total of 374 clinician-reported patients with psoriasis and suspected/confirmed COVID-19 from 25 countries. Approximately 71% of these patients were receiving a biologic agent, whereas 18% of patients were receiving a non-biologic agent and 10% were receiving no systemic therapy for psoriasis. The majority of patients in the registry (93%) fully recovered from COVID-19. About 21% (n=77) of patients were hospitalized, and 2% (n=9) died.

An increased risk for hospitalization was associated with older age (multivariable-adjusted odds ratio [OR], 1.59 per 10 years; 95% CI, 1.19-2.13), male sex (OR, 2.51; 95% CI, 1.23-5.12), non-white ethnicity (OR, 3.15; 95% CI, 1.24-8.03), and comorbid chronic lung disease (OR, 3.87; 95% CI, 1.52-9.83).

Patients in the PsoProtect registry who used non-biologic systemic therapies were more frequently hospitalized compared with patients who received biologic agents (OR, 2.84; 95% CI, 1.31-6.18).

In the PsoProtectMe registry including 1626 patients from 48 countries who provided self-reported data, the researchers found lower levels of social isolation in patients who received non-biologic systemic therapy vs biologic agents (OR 0.68; 95% CI, 0.50-0.94).

A limitation of this study is its potential lack of generalizability, due to the inclusion of only patients with moderate to severe psoriasis and the high volume of patients from Spain, Italy, and the United Kingdom.

The investigators of this study emphasize that more data are necessary to clarify these observations before any recommendations for changes in clinical practice can be considered, adding that further investigation of the observed differential rate of hospitalization between different classes of biologics is warranted.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis insights from a global registry-based study. Published online October 16, 2020. J Allergy Clin Immunol. doi:10.1016/j.jaci.2020.10.007

Go here to see the original:

Biologic Agent Use Associated With Lower Hospitalization Risk for Patients With Psoriasis and COVID-19 - Dermatology Advisor

Psoriasis Treatment Market research report is the new statistical data source added by A2Z Market Research.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280493

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc.

The key questions answered in this report:

What will be the Market Size and Growth Rate in the forecast year?What are the Key Factors driving Psoriasis Treatment Market?What are the Risks and Challenges in front of the market?Who are the Key Vendors in Psoriasis Treatment Market?What are the Trending Factors influencing the market shares?What are the Key Outcomes of Porters five forces model?Which are the Global Opportunities for Expanding the Psoriasis Treatment Market?

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=280493

Global Psoriasis Treatment Market Segmentation:

Market Segmentation by Type:

TNF InhibitorsInterleukinsOthers

Market Segmentation by Application:

Hospital PharmaciesRetail PharmaciesOnline pharmacies

Regions Covered in the Global Psoriasis Treatment Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Psoriasis Treatment market.Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Psoriasis Treatment market.

Table of Contents

Global Psoriasis Treatment Market Research Report 2020 2026

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

The rest is here:

Comprehensive Report on Psoriasis Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Sun Pharmaceutical Industries...

What are the emerging opportunities in the Chronic Plaque Psoriasis Therapeutics Market?

Currently, significant business sectors are going through changes. This has prompted huge benefits for a few and misfortunes for other people. To make the most out of the emerging chances, you can exploit the most granted Chronic Plaque Psoriasis Therapeutics market report. It offers nitty-gritty experiences into the market. This will doubtlessly manage their organizations in creating the following move over the impending industry quarters.

It must be noticed that the Chronic Plaque Psoriasis Therapeutics market is encountering unexpected ascent in reception by numerous new players (from MNCs to SMEs). It is because of the way that even with the market turbulences the Global market came out with solid numbers. With the new business running into the market, it is basic to stand apart from the group. The customers can undoubtedly accomplish this utilizing the means referenced in the Chronic Plaque Psoriasis Therapeutics market report.

What type of investigation is done in the Chronic Plaque Psoriasis Therapeutics market report?

Analysis of various socioeconomics for venturing into the market is important as it will hugely affect the development throughout the following coming years. The Chronic Plaque Psoriasis Therapeutics market report is planned subsequent to doing long periods of exploration and the information sifted through in the report was gathered from dependable sources, for example, government sites.

As the market is gigantic, it turns out to be imperative to comprehend the market from its underlying foundations. Get a superior perspective on the Chronic Plaque Psoriasis Therapeutics market through the data referenced in the committed areas of the report. With this, the customers likewise get a perspective on the business structure of the contenders.

What are the reasons that impact the growth of the Chronic Plaque Psoriasis Therapeutics Market?

As of late, the advanced transformation has pushed the associations in changing into a computerized business for coming to the intended interest group present over the globe. The Chronic Plaque Psoriasis Therapeutics market report shares the significance of neighborhood language, partners, and political situation that will drive the Global market higher than ever.

With the best possible comprehension of the Chronic Plaque Psoriasis Therapeutics market, the associations can hop onto the open doors that will bring productive outcomes. The customers can exploit the biggest in-house information base for taking the most effective actions. Likewise, the Chronic Plaque Psoriasis Therapeutics market report has committed segments covering the insights concerning the current market players. With the information on how they function and accomplish their objectives, your business can likewise be formed as needs be.

What type of analysis short-term or long-term is added in the Chronic Plaque Psoriasis Therapeutics Market report?

This is important to sidestep any negative circumstances that may affect the development of the organizations. In addition, the associations need to comprehend Porters five powers that shape the market elements. In the event that the customers wish to add or eliminate the names of the organizations, it tends to be done, to suit the desires for the clients, for accomplishing long-haul objectives. SWOT investigation helps in uncovering the qualities and shortcomings of the business. The PESTLE investigation helps in checking the outer elements that shape the market overall. Subsequently, for making a name in the Chronic Plaque Psoriasis Therapeutics market, it gets important to get thought from both SWOT and PESTLE investigations.

The Chronic Plaque Psoriasis Therapeutics market report likewise brushes over the significance of language and partners for the smooth working of the associations. Thusly, the customers are stacked with data and steps and are prepared to move into the market for accomplishing the ideal objectives.

About Us:

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Reports provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

The rest is here:

Chronic Plaque Psoriasis Therapeutics Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2027 - Cheshire Media

This report gives a vital investigation of the Global Plaque Psoriasis Treatment market and the development gauges for the conjecture time frame. This report likewise gives market estimating and figures to the Global Plaque Psoriasis Treatment market.

Some of the players in Plaque Psoriasis Treatment Market areNovartis AG (Switzerland),AbbVie Inc.(U.S),Amgen, Inc. (U.S),Johnson & Johnson (U.S),Eli Lilly and Company (U.S),Celgene Corporation (U.S),Sun Pharmaceuticals Industries Ltd. (India)

Request free sample copy of thishttps://www.precisionbusinessinsights.com/request-sample?product_id=23496

The most recent market report on Plaque Psoriasis Treatment industry offers a top to bottom investigation of this business vertical including key data concerning industry expectations, transcendently showcase inclinations, advertise size, piece of the overall industry, present valuation, and benefits estimations for the gauge time frame. The concise data in regards to the business additionally breaks down and clarifies the Plaque Psoriasis Treatment market development rate in the conjecture course of events, prompted by specific impetuses, a substance of which has been given in this exploration report related to the essential difficulties and development prospects present in the business.

Statistical surveying Place has included a report, Global Plaque Psoriasis Treatment Market Research Report 2020-2026 incorporates a careful investigation of the Plaque Psoriasis Treatment advertise in the anticipated period. Worldwide Plaque Psoriasis Treatment market report offers the most recent industry patterns, mechanical developments and figure showcase information. A profound jump perspective on Plaque Psoriasis Treatment industry dependent on market size, Plaque Psoriasis Treatment development, advancement plans, and openings is offered by this report. The estimate advertises data, SWOT examination, Plaque Psoriasis Treatment hindrances, and attainability study are the fundamental angles broke down in this report.

Request Customization athttps://www.precisionbusinessinsights.com/request-customisation?product_id=23496

Key Features of the Report:

There are 10 Chapters to deeply display the Plaque Psoriasis Treatment market.Chapter 1 to analyze the top manufacturers of Plaque Psoriasis Treatment, with sales, revenue and price of Plaque Psoriasis Treatment in 2020 and 2026.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2026.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Plaque Psoriasis Treatment, for each region, from 2020 and 2026.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2020 and 2026.

Chapter 10 Plaque Psoriasis Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 and 2026.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our Plaque Psoriasis Treatment is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Read more from the original source:

Plaque Psoriasis Treatment Market to receive overwhelming hike in Revenues by 2026 Novartis AG (Switzerland),AbbVie Inc.(US),Amgen, Inc. (US) -...

Psoriasis is an autoimmune condition and cannot be cured completely. The current treatment methods, to an extent, effectively work in controlling the disease. Hence, the opportunities for consumption remains worthy for players in the globalpsoriasis treatment marketin the coming years. However, with time, companies would want to stay ahead in the league and hence are working on developing drugs that are more effective. The current drug pipeline appears to be promising and any launch in the next few years will have a significant impact on the growth of the global psoriasis treatment market.

Transparency Market Research has recently published a report on the global psoriasis treatment market. It states that the market is expected to grow at a decent rate of 5.10% CAGR during 2016 to 2024. The potential players in the global psoriasis treatment market include LEO Pharma, AbbVie, AstraZeneca, Pfizer, and Biogen.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17960

Rise in Psoriasis Cases to Favor Growth

The overall number of cases of psoriasis has steadily increased. While the incidence of the disease is on the rise due to several factors that trigger gene mutation such as pollution and lifestyle habits. At the same time, the general awareness among the public about the disease is considered to be the larger reason for the rise in number of cases. With internet and social media presence, healthcare organizations and governments have been able to conduct awareness campaigns that reach out to the people. As a result, people have realized the importance of early diagnosis and timely treatment for the disease. This has been one of the largest factors for growth in the global psoriasis treatment market.

While there has been general awareness among the public, governments across the world have taken initiatives to help people suffering from these conditions, especially in the rural areas. Consistent campaigns and efforts to ensure people from the rural and deeper areas where the access to healthcare is poor, has raised the demand for products in the global psoriasis treatment market.

Request for Analysis of COVID19 Impact on Psoriasis Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=17960

Favorable Healthcare System to Augment Growth in North America

Undoubtedly the developed healthcare system in North America, especially the United States, favors growth for the global psoriasis market. The regulated healthcare system coupled with organized policies that aid in diagnosing diseases and treating them on time have been of solid support to all healthcare markets. At the same time, the buzzing pharmaceutical business environment keeps the North American region sound for business. These aspects have a substantial impact on the growth of the global psoriasis treatment market.

Besides North America, Europe and Asia Pacific will also remain important for players in the global psoriasis treatment market. Companies will be looking to explore business potential in new areas in the coming years to be able to expand and sustain in the business.

Buy Psoriasis Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=17960&ltype=S

The global psoriasis treatment is segmented based on

Drug Class

Route of Administration

Distribution Chanel

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the original post:

Psoriasis Treatment Market expected to grow at a decent rate of 5.10% CAGR during 2016 to 2024 - The Haitian-Caribbean News Network

A variety of health issues can cause bumps to form on the scalp, including folliculitis, acne, head lice, and eczema.

Many causes of bumps in this area are harmless, but receiving a prompt diagnosis and treatment can address any concerns and resolve the issue quickly.

In this article, learn about the health conditions that can lead to bumps on the scalp and when to contact a doctor.

Acne that forms on the scalp can be similar to acne in other areas. A person may have raised bumps, whiteheads, or blackheads, which may be itchy, sore, or tender.

Scalp acne occurs when pores or hair follicles become clogged with dead skin cells or oil. If a person has oily hair or adds certain products to their hair, they might be more susceptible to scalp acne.

Factors that may contribute to scalp acne include:

If scalp acne develops consistently, wash the hair more thoroughly, and try hypoallergenic hair products.

If the issue persists or gets worse, contact a dermatologist for specific guidance.

Learn more about treatments for scalp acne.

Folliculitis is a common infection that develops in hair follicles. It can look similar to acne and causes raised, round, inflamed, and itchy bumps.

The infection develops when bacteria enter damaged follicles, and the underlying cause may involve:

To relieve any pain and help the skin heal, apply a warm compress to the area three or four times a day, for 20 minutes at a time.

If the issue worsens, or the cause is unclear, contact a dermatologist.

Itchiness is the most common symptom of head lice, but bumps on the scalp can also indicate their presence.

Have someone closely examine the area for white eggs or moving lice.

Treatment for head lice typically involves using medicated shampoo and combing the area to kill and remove the bugs and their eggs.

Learn more about treatment for head lice here.

There are many types of eczema, and two that can affect the scalp include:

This type of eczema can develop anywhere on the body, including the scalp.

It causes the skin to become inflamed. On a person with darker skin, the affected areas may become darker, grayish, or purplish. On a person with lighter skin, the areas may redden.

In children, it typically affects the hands, backs of the knees, insides of the elbows, scalp, and face.

Adults with this chronic form of eczema on the scalp may notice color changes such as redness, as well as swelling and greasy scaling.

Beyond the scalp, seborrheic dermatitis can affect the:

For eczema on the scalp, try medicated shampoos, creams, or ointments.

Learn more about the treatments for scalp eczema.

Contact dermatitis occurs when the skin comes into contact with an allergen or irritant.

When this issue develops on the scalp, hair products containing fragrances or specific chemicals may be responsible.

When the scalp reacts to an irritant or allergen, such as a chemical, it can cause itchiness, a burning sensation, and sometimes blistering.

The reaction can occur within minutes of contact with the irritant.

It is important to avoid further contact with products that may be responsible. Also, a doctor may prescribe topical steroids.

These fluid-filled cysts most commonly develop on the scalp. They form in the hair follicles and contain excess keratin, a protein that occurs in the hair, nails, and skin.

The cysts are typically large and smooth, and they may be tender. Sometimes, more than one occurs in one area.

Pilar cysts typically go away on their own. To reduce the swelling and any tenderness, try applying a warm, clean washcloth to the area.

If a cyst becomes infected, a doctor may prescribe antibiotics. Also, a doctor may recommend the surgical removal of a cyst.

Learn more about the treatments for pilar cysts here.

Hives are a rash consisting of itchy, raised bumps. The rash forms as part of an allergic response, and it can affect any part of the body, including the scalp.

Hives usually go away on their own within a few days. However, a doctor can prescribe antihistamines or corticosteroids.

Learn more about the treatments for hives.

Ringworm is a fungal infection of the skin, and it can form on the scalp. Healthcare professionals may refer to this as tinea capitis.

Symptoms include:

Tinea capitis is more common in children than adults.

Creams, powders, and lotions do not work for ringworm on the scalp. Instead, a doctor prescribes an oral antifungal medication that a person must take for 13 months.

Melanomas can appear on the scalp, as can:

Unlike the other bumps or blemishes described above, lumps caused by skin cancer continue to change shape and size.

If any bumps on the scalp may indicate cancer, contact a dermatologist immediately.

After making a diagnosis, the doctor will describe the treatments, including surgical and nonsurgical options.

A person can treat most of the health issues that cause bumps on the scalp at home, with care strategies, such as using warm compresses or switching shampoos, and over-the-counter medications.

However, contact a healthcare provider about any unusual growths or symptoms of ringworm or atopic dermatitis.

Also, if any scalp issue persists or worsens, consult a dermatologist.

Bumps on the scalp can result from a variety of health issues, such as acne, eczema, psoriasis, pilar cysts, hives, or ringworm.

Some causes of bumps, such as skin cancer, require urgent medical attention. But often, a person can address the issue at home.

If any lump, bump, or blemish on the scalp is concerning, or if home care is ineffective, contact a dermatologist or another healthcare professional.

See more here:

Bumps on the scalp: Causes, symptoms, and treatments - Medical News Today

BARCELONA, Spain, Oct. 13, 2020 /PRNewswire/ -- Almirall, S.A. (ALM)announced today that it has signed an agreement with the French Authorities to make the biologic treatment ILUMETRI (tildrakizumab), a high-affinity IL-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy.

The agreement has been signed after the Commission of Transparency of the Haute Autorit de Sant(HAS), the French National Health Authority, provided a favourable opinion for the reimbursement in France of ILUMETRI (tildrakizumab) on June 3rd and considered the actual benefit (Service Mdical Rendu or SMR) as "important". Theprevalenceof chronic plaque psoriasis among theFrenchpopulation is around 5,6%.

Following the publication of the agreement in the French Official Journal, Ilumetri (tildrakizumab) will be included in the list of reimbursable medicines by the social insurance for the treatment of adults with severe chronic plaque psoriasis.

"Today's announcement represents great news for those patients with severe psoriasis across France who can count on a safe and convenient biological treatment for their condition. Ilumetri provides sustained high efficacy and safety, and improves patients' quality of life"said Alfredo Barn, Chief Commercial Officer of Almirall. "We are glad we could collaborate with French authorities to find an agreement to provide sustainable access to an additional biologic treatment option for patients suffering from this skin disease through a national reimbursement agreement," he added.

Ilumetri (tildrakizumab) is the first biologic marketed by Almirall and constitutes an important step forward in the treatment of moderate-to-severe chronic plaque psoriasis. Since its approval by the European Commission in November of 2018, the product has been,offering a decisive benefit to patients as it has the longest efficacy and safety data among the IL23p19s.Ilumetri is reimbursed in 10 countries around Europe, including recent agreements in Belgium and Italy.

Tildrakizumab is administered by subcutaneous injection. Its dosing regimen, with lower frequency of injections, only 4 injections per year during maintenance1, offers convenience and quality of life for patients, potentially achieving an improved treatment satisfaction and improving adherence to treatment.

References

SOURCE Almirall, S.A. (ALM)

Original post:

Almirall, SA (ALM) announces approval of the reimbursed price for Ilumetri (tildrakizumab) in France for the treatment of adult patients with severe...

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a key opinion leader discussion on the unmet need in psoriasis and atopic dermatitis, including the potential of EDP1815 to serve as a new therapeutic option for patients living with mild to moderate disease. The event will be held virtually on Thursday, October 22, 2020 from 9:00 a.m. to 10:30 a.m. ET.

As part of the event, Benjamin Ehst, M.D., Ph.D., Board-certified Dermatologist, Investigator and Clinical Associate Professor with the Oregon Medical Research Center, will discuss the current treatment landscape and unmet need in psoriasis. Additionally, Evelo management will host a panel discussion with Dr. Ehst to review the opportunity for EDP1815 in atopic dermatitis. Evelos management team will also review the design of its recently initiated Phase 2 trial in psoriasis and provide an overview of the clinical data generated with EDP1815 to date, as well as the Companys platform and upcoming milestones.

To access the live event, please dial (866) 795-3242 (domestic) or (409) 937-8909 (international) and refer to conference ID 1552379. A live webcast of the event will also be available under News and Events in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Dr. Benjamin EhstDr. Benjamin Ehst is a board-certified dermatologist and clinical associate professor at Oregon Medical Research Center.

Dr. Ehst spent his early career at Oregon Health & Science University (OHSU) as an associate professor in the Department of Dermatology. He honed his specialty in psoriasis as a member of the Center of Excellence in Psoriasis and Psoriatic Arthritis, eventually taking over as co-director of the multidisciplinary center. Additionally, Dr. Ehst organized a specialty clinic caring for skin-related issues in HIV-infected individuals.

Alongside patient care and teaching, Dr. Ehst began his work in clinical research while at OHSU, acting as lead investigator for studies on treatments for skin diseases such as atopic dermatitis, psoriasis, granuloma annulare, actinic keratosis and melanoma.

Dr. Ehst earned his undergraduate degree from the University of Chicago and his medical and doctoral degrees at the University of Minnesota in a combined Medical Scientist Training Program. He received his residency training in Dermatology at the Johns Hopkins Hospital in Baltimore and solidified his interest in medical practice and clinical research while studying the immune response to malaria at the Hopkins Bloomberg School of Public Health.

About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The companys first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit http://www.evelobio.com and engage with Evelo on LinkedIn.

ContactEvelo BiosciencesJessica Cotrone, 978-760-5622jcotrone@evelobio.com

Go here to read the rest:

Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for...

What's more, there was a correlation between the severity of psoriasis and high blood pressure.

According to the NHS, in severe cases of psoriasis, the skin around your joints may crack and bleed.

"Treatments are determined by the type and severity of your psoriasis, and the area of skin affected," explains the health body.

It adds: "Your doctor will probably start with a mild treatment, such as topical creams applied to the skin, and then move on to stronger treatments if necessary."

If your psoriasis is linked to high blood pressure, you should overhaul aspects of your lifestyle to lower you reading.

Improving your diet is integral to this effort and one of the quickest and most effective countermeasures is to cut back on salt.

According to Action on Salt, a research outfit based at Queen Mary University of London, a high salt diet disrupts the natural sodium balance in the body.

"This causes the body to retain water, which increases the pressure of the pushing of blood against the vessel walls," warns the health body.

"As a nation, if we can cut one gram of salt from our average daily salt intake, there would be approximately 6,000 fewer deaths from strokes and heart attacks each year in the UK," it says.

According to the NHS, eating a low-fat diet that includes lots of fibre, such as wholegrain rice, bread and pasta, and plenty of fruit and vegetables also helps lower blood pressure.

"Being active and taking regular exercise lowers blood pressure by keeping your heart and blood vessels in good condition," notes the health body.

Adults should do at least 150 minutes (two hours and 30 minutes) of moderate-intensity aerobic activity, such as cycling or fast walking, every week, it adds.

Read more from the original source:

High blood pressure warning - the change on your skin that could signal you're at risk - Express

Interim data expected by mid-2021

CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it has dosed the first patients in its Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. EDP1815 is an investigational oral biologic in development for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19.

We are pleased to announce the dosing of the first patients in our Phase 2 clinical trial in mild to moderate psoriasis, said Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer of Evelo. In Phase 1b studies, EDP1815 demonstrated an ability to resolve systemic inflammation and provide clinical benefit to patients with psoriasis. Based on these data, EDP1815 may offer an improved profile to existing products and others in development. EDP1815 has the potential to be an effective, well-tolerated, and convenient medicine for millions of patients with mild to moderate psoriasis. Our Phase 2 trial, if successful, will enable us to advance into confirmatory registrational studies, following meetings with health authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). We look forward to interim data by mid-2021, as we continue to progress this important therapy toward market.

EDP1815-201 is a double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in 225 patients with mild to moderate psoriasis over a 16-week treatment period. The primary endpoint is mean reduction in Psoriasis Area and Severity Index (PASI) score at 16 weeks. Key secondary endpoints include other clinical measures of disease such as Physicians Global Assessment (PGA), Body Surface Area (BSA), PGA x BSA, Psoriasis Symptom Inventory (PSI), Dermatology Life Quality Index (DLQI), and Lesion Severity Score (LSS). Interim data from the study is expected by mid-2021.

About EDP1815 in Psoriasis EDP1815 is an investigational oral biologic being developed for the treatment of inflammatory diseases.EDP1815 is a strain ofPrevotella histicola, selected for its specific pharmacology. In thesecondandthirdquarter of 2019, Evelo reported positive Phase 1b interim clinical data in two cohorts of patients with mild to moderate psoriasis. EDP1815 was well tolerated at both doses, with no overall difference reported from placebo. There was a reduction in mean LSS and PASI score after 28 days of dosing in both cohorts who received EDP1815. In the high dose cohort alone, there was a continued reduction in both mean LSS (of 24% vs. placebo of 7%) and PASI score (of 21% vs. placebo of 3%) at 42 days 14 days following the last dose of the drug. This may indicate a sustained clinical effect and dose response. EPD1815 was also observed to limit the systemic production of multiple inflammatory cytokines, including IL-6, IL-8, TNF, and IL-1, which are well-established mediators of potentially harmful effects in patients with inflammatory diseases.

About PsoriasisPsoriasis is a common chronic immune-mediated inflammatory skin disease, affecting up to 3% of the population worldwide. The disease is driven by Th17-inflammation, which results in the formation of thickened red plaques with scaling. Psoriatic lesions can appear anywhere on the body but are most often seen on the knees, elbows, scalp, and lumbar area. There is a strong association with psoriatic arthritis, depression, and metabolic syndrome.

Patients with mild to moderate psoriasis are underserved by current treatments, including topical therapies, which do not control systemic inflammation, have low rates of compliance, or in the case of potent topical steroids, are not recommended for long-term use. The majority of novel therapies, including injectable high-cost biologics, are only approved for patients with moderate to severe disease. Even in this patient population, the majority of eligible patients do not receive biologics, instead opting for topical or oral systemic therapies, which are associated with tolerability issues and/or with monitoring requirements tied to safety concerns.

About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The companys first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit http://www.evelobio.com and engage with Evelo on LinkedIn.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the timing and results of any clinical trials or readouts for EDP1815, our development plans, and the promise and potential impact of EDP1815 or our other product candidates.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our reliance on third parties and collaborators to expand our microbial library, conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; our management and principal stockholders have the ability to control or significantly influence our business; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us.

These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

ContactJessica Cotrone, 978-760-5622jcotrone@evelobio.com

Here is the original post:

Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis - GlobeNewswire

SIMPONI ARIA (golimumab) is a fully human monoclonal antibody used for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA). Credit: Janssen Biotech, Inc. The 4ml single-use vial of SIMPONI ARIA contains 50mg of golimumab. Credit: A2-33. SIMPONI ARIA acts as a tumor necrosis factor (TNF)-blocker.

SIMPONI ARIA (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody.

It is indicated for the treatment of moderate-to-severe active rheumatoid arthritis (RA) and active ankylosing spondylitis (AS) in adult patients, as well as active polyarticular juvenile idiopathic arthritis (pJIA) and active psoriatic arthritis (PsA) in patients aged two years and older.

SIMPONI ARIA is available in a single-use vial as a colourless to a light-yellow solution in 50mg / 4ml (12.5mg / ml) dosage strength for intravenous administration.

Discovered and developed by Janssen Biotech, golimumab was initially approved as a subcutaneous injection under the trade name Simponi by the US Food and Drug Administration (FDA) for the treatment of RA, PsA and AS in adult patients in 2009.

SIMPONI was approved in Europe for the treatment of moderate-to-severe RA, active and progressive PsA, severe, active AS, active ulcerative colitis, severe active non-radiographic axial spondyloarthritis and pJIA.

In July 2013, the intravenous form of golimumab obtained FDA approval under the trade name Simponi Aria for the treatment of moderate-to-severe active RA in combination with methotrexate (MTX).

The company submitted two supplemental biologics license applications (sBLAs) for Simponi Aria to the FDA for the treatment of PsA and AS in adult patients in December 2016. The applications were approved in October 2017.

The FDA also received two sBLAs for Simponi Aria for the treatment of active pJIA and PsA in paediatric patients in April 2020. The drug was approved for the indications in September 2020.

SIMPONI ARIA is marketed in 24 countries for one or more of the aforementioned indications.

Juvenile idiopathic arthritis (JIA), previously known as juvenile rheumatoid arthritis, is an arthritis-like inflammatory condition in children characterised by joint swelling, stiffness and pain, persistent for at least six weeks.

The polyarticular form of JIA is most common and is characterised by inflammation in more than four joints, closely resembling adult RA.

PsA is a chronic inflammatory disease characterised by both joint inflammation and skin lesions associated with psoriasis. PsA in paediatric patients is one of the rarest forms of JIA, observed in 2% to 11% of JIA patients.

Other characteristics of psoriatic arthritis include finger and nail defects or complications with the eye.

Golimumab is an anti-TNF biologic agent that binds to soluble and transmembrane bioactive forms of human TNF-alpha, a cytokine protein whose overproduction in the body leads to several chronic inflammatory diseases.

Inhibition of the interaction of TNF-alpha to its receptors inhibits its biological activity.

FDA approval of SIMPONI ARIA for pJIA is based on results from the open-label, multi-centre, phase three clinical trial, GO-VIVA.

SIMPONI ARIA is available in a single-use vial as a colourless to a light-yellow solution in 50mg / 4ml (12.5mg / ml) dosage strength for intravenous administration.

The trial evaluated the safety and efficacy of SIMPONI ARIA in 127 patients with pJIA aged two years to 17 years, following MTX treatment for at least two months.

The efficacy of the drug was consistent with responses in adult patients with RA through 52 weeks.

SIMPONI ARIAs pharmacokinetic (PK) exposure was consistent with the two pivotal phase three clinical trials in adult patients with moderate-to-severe active RA and active PsA.

The safety profile established for SIMPONI ARIA in paediatric patients was also consistent with the results in adult RA and PsA patients.

Common side-effects of SIMPONI ARIA reported in patients during the clinical trial are viral infections, upper respiratory tract infection, increased levels of alanine aminotransferase and aspartate aminotransferase, decreased neutrophil count, rash, bronchitis and high blood pressure.

Read more from the original source:

SIMPONI ARIA (golimumab) for the Treatment of pJIA - Clinical Trials Arena

Chronic Plaque Psoriasis Therapeutics Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Chronic Plaque Psoriasis Therapeutics Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Chronic Plaque Psoriasis Therapeutics market is covered in the report.The Chronic Plaque Psoriasis Therapeutics Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Chronic Plaque Psoriasis Therapeutics Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Chronic Plaque Psoriasis Therapeutics industry.

The Global Chronic Plaque Psoriasis Therapeutics Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.

An Outline of the Major Key Players covered in this Report:

Abbvie, Novartis International, Pfizer, Merck, Astelllas Pharma, GlaxoSmithKline

Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Chronic_Plaque_Psoriasis_Therapeutics_/16952/sample

Note: We can also provide market report in German/French Language.

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Chronic Plaque Psoriasis Therapeutics Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split into

ClinicalNon-ClinicalInactive

Major applications/end users, including

HospitalsAmbulatory Surgical CentersOthers

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Chronic_Plaque_Psoriasis_Therapeutics_/16952/inquiry

The research offers an analysis of the geographical landscape of the Chronic Plaque Psoriasis Therapeutics Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Chronic Plaque Psoriasis Therapeutics market.

Major Highlights of TOC Covers:

Chronic Plaque Psoriasis Therapeutics Market 2020, Chronic Plaque Psoriasis Therapeutics Market size, Chronic Plaque Psoriasis Therapeutics Market share, Chronic Plaque Psoriasis Therapeutics Market analysis, Chronic Plaque Psoriasis Therapeutics Market forecast, Chronic Plaque Psoriasis Therapeutics Market trends, Chronic Plaque Psoriasis Therapeutics Market Research report, Chronic Plaque Psoriasis Therapeutics application, Chronic Plaque Psoriasis Therapeutics Trends, Chronic Plaque Psoriasis Therapeutics Market growing CAGR, Chronic Plaque Psoriasis Therapeutics Market Competitive Landscape, Chronic Plaque Psoriasis Therapeutics Market Growth

Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Chronic Plaque Psoriasis Therapeutics Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com

Continue reading here:

COVID-19 Impact on Chronic Plaque Psoriasis Therapeutics Market New Trends, Size, Share, Growth, Outlook, Overview, Application and Forecast 2020 to...

Oct. 13, 2020 11:00 UTC

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will host a conference call with investors to provide an update on its Phase III psoriasis study and the positive interim data analysis and recommendations from the studys Independent Data Monitoring Committee (IDMC). Dr. Michael Goldfarb, M.D., Dermatologist, Beaumont Hospital, Dearborn, Michigan, U.S., a key opinion leader in the treatment of psoriasis, will join the call which is scheduled to take place on Thursday, October 15, 2020 at 4:15 pm EDT.

Piclidenoson, Can-Fites lead drug candidate, offers several potential key benefits over psoriasis treatments currently on the market. As an oral pill taken twice daily, it offers ease of administration for patients who tend to prefer oral medications over injectables. As an oral drug, the Company believes Piclidenoson may be priced at a significantly lower cost than injectable biologics, and somewhat lower than the current oral medication on the market, Otezla. A 2018 study on psoriasis patient preferences published in American Health & Drug Benefits showed the two most important considerations for choosing a psoriasis drug were route of administration and cost, with oral administration and lower cost being most preferred.

Piclidenoson has been dosed in over 1,500 patients with an excellent safety profile in clinical trials to date. In contrast, the biologics on the market approved to treat psoriasis have black box warnings. While psoriasis is a serious disease with quality of life implications for patients, it is not life threatening and therefore patients recognize that while they need a treatment that is effective, safety is also a very high priority.

With an estimated 125 million cases worldwide, psoriasis is considered an immune system problem that causes infections, stress and is a chronic disease with no cure. The market size for psoriasis is estimated to be $11.5 billion at the end of 2020.

The call will take place on Thursday, October 15th 2020 at 4:15 pm EDT. Investors in the U.S. are invited to dial 1-877-423-9813. International investors may dial 1-201-689-8573. The conference ID is 13711928.

Investors may also participate via webcast: http://public.viavid.com/index.php?id=141970

A replay of the webcast will be archived on Can-Fites website for a period of time.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for rheumatoid arthritis/psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should or anticipate or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005454/en/

Read the original:

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 - BioSpace

Secukinumab may be a safe and effective treatment for patients with psoriatic disease, comorbidities, and treatment failure, according to results of a retrospective study published in Dermatologic Therapy. The fully human IgG1/k monoclonal antibody has been shown to be safe and effective in the treatment of psoriasis in phase 3 trials, but has not yet been tested in the general population.

To determine the clinical effectiveness and safety of secukinumab in a real-life cohort of patients with moderate to severe psoriasis vulgaris, data from 120 patients (35.8% women) were analyzed. The mean age of participants was 49.813.5 years and 65% of participants were diagnosed with additional forms of psoriasis. The extent and severity of psoriasis was measured using the Psoriasis Area Severity Index (PASI).

After 3 months of secukinumab therapy, the mean PASI of the entire population was significantly lower than baseline (P <.001) and was maintained at 12 month follow-up (P <.001). Total clearance (PASI 0) was achieved after 12 months in 46% of those with psoriatic onychopathy (1 of the more difficult forms of psoriasis to treat), 75% of patients with moderate to severe scalp psoriasis, 57% of patients with psoriasis of the genital area, and 38% of patients with palmoplantar psoriasis. In all, 28 adverse effects were recorded in the first year of treatment, resulting in 8 patients discontinuing treatment. After 12 months, patients who had been unresponsive to 2 or more lines of biologic agents had a lower rate of treatment persistence (71%) than those who were bio-naive (93%) or had a history of inefficacy to only 1 biologic agent (88%)(P =.009 for trend).

Limitations to this study include its small cohort and retrospective design. Future research with a larger cohort and that investigates the impact of body mass index on therapeutic effectiveness are warranted.

The results of this study indicated to the researchers that secukinumab is effective and safe in the treatment of psoriasis in patients with a range of comorbidities and in areas that are difficult to treat. These results were significant despite a mean persistence to treatment of 85% after 12 months.

Disclosure: Medical writing assistance for this publication was provided by Novartis. Please see the original reference for a full list of authors disclosures.

Reference

Carpentieri A, Mascia P, Fornaro M, et al. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study. [published online July 18, 2020]. Dermatol Ther. doi:10.1111/dth.14044

Follow this link:

Secukinumab Effective in Real-Life Patients With Moderate-Severe Psoriasis - Dermatology Advisor

A recent Cochrane review suggests very few studies offer sufficient evidence supporting the efficacy and safety of exposure to artificial ultraviolet (UV) B while soaking in an indoor salt bath, an approach termed balneophototherapy, for the treatment of chronic plaque psoriasis. Abridged findings from this review were published in the British Journal of Dermatology.

An international team of researchers reviewed 8 randomized controlled trials consisting of 1976 participants with psoriasis. In 6 trials, different treatments were applied to different participants, whereas 2 other trials examined different treatments applied to the same participant but to different body parts.

Across all studies, the mean age for participants ranged between 41 to 50 years, and the median Psoriasis Area and Severity Index (PASI) score ranged from 15 to 18 across 5 studies. Only 1 trial examined salt baths plus UVB vs other treatments without UVB (ie, psoralen bath plus UVA). Trials spanned from 2 to 13 months in duration.

Several limitations affected the researchers confidence in the evidence of these trials. These limitations included risk for bias, such as in terms of inadequate blinding and high probability of publication bias. The researchers noted that commercial spa or salt companies sponsored 3 studies, health insurance companies sponsored 1 study, a dermatologist association sponsored 1 study, and 3 studies had no reported funding sources.

In addition, reporting of the reviewers specified outcomes including Dermatology Life Quality Index, pruritus severity using a visual analogue scale from 0 (no itching) to 100 (severe itching), time to relapse, and secondary malignancies were either limited or nonexistent.

According to the researchers who conducted this Cochrane review, further randomized controlled trials are needed to evaluate PASI 75 and even PASI 90 or 100, in addition to treatment-related adverse events requiring withdrawal, to gain a deeper understanding of the efficacy and safety of balneophototherapy. To consider any potential harm by UVB exposure, they wrote, future study protocols should include long-term observations.

Dislcosure: Please see the original reference for a full list of authors disclosures.

Reference

Peinemann F, Harari M, Peternel S, et al. Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis: abridged Cochrane review. Published online July 6, 2020. Br J Dermatol. doi:10.1111/bjd.19385

Originally posted here:

More Long-Term Randomized Trials Are Needed to Support Balneophototherapy for Chronic Psoriasis - Dermatology Advisor